FDA Advisory Panel Votes to Add BPC-157 Peptide to Compounding List

1-Minute Brief

The decision could increase access to BPC-157, a peptide with limited human research, raising regulatory and safety questions.

Key Facts

• An FDA advisory committee voted on Thursday to add BPC-157 to a drug compounding list.
• The vote marks a win for US Health Secretary Robert F Kennedy, who supports these drugs.
• BPC-157 is a peptide that has gained popularity online.
• The drugs have not been well studied for human use, according to BBC News.
• The FDA advisory committee's decision was reported by ABC News.

What Happened

An FDA advisory committee voted to add the peptide BPC-157 to a drug compounding list, a move reported by both ABC News and BBC News.

Why It Matters

Adding BPC-157 to the compounding list may make it more widely available, despite limited research on its effects in humans. The decision has drawn attention due to the peptide's online popularity and support from a high-profile official.

What's Next

Regulators may issue further guidance on the use of BPC-157. Additional research or policy discussions regarding the safety and efficacy of such peptides may follow.